Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.76 |
| ▸ | PDE5A | O76074 | 5/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.62 |
| ▸ | PDE11A | Q9HCR9 | 5/20 | 0.62 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.62 |
| ▸ | PDE2A | O00408 | 4/20 | 0.62 |
| ▸ | PDE8A | O60658 | 4/20 | 0.62 |
| ▸ | PDE9A | O76083 | 3/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349193 | 0.93 | PDE4A (0.65) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL2417050 | 0.90 | PDE4A (0.73) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL12281231 | 0.89 | PDE4A (0.71) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL16557132 | 0.88 | PDE4A (0.70) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL2362440 | 0.86 | PDE4A (0.64) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL20341398 | 0.86 | PDE4A (0.74) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8046132 | 0.86 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL21143267 | 0.85 | PDE4A (0.97) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL20341397 | 0.84 | PDE4A (0.62) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL18349192 | 0.84 | PDE4A (0.63) | PDE4APDE5APDE3BPDE11APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE5A 1/4885PDE3B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.